A Phase 2 interventional study of Necitumumab and Gemcitabine in Malignant Solid Tumor, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, 2 under way, none of them phase 3. necitumumab · Carcinoma, Non-Small-Cell Lung.
Among the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
necitumumab: first FDA approval 2015 (PORTRAZZA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 13 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 119th largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 73 in phase 2, and was the 93rd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing necitumumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT02496663National Cancer Institute (NCI)Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
Biological: Necitumumab · Drug: Gemcitabine · Drug: Cisplatin
PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product
Also known as: IMC-11F8, LY3012211
PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2) Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2
Also known as: Gemzar®, LY188011
PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2 Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab
Time frame: Run-In Period Day 3 Cohort 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 Hour (h) Post Start of Infusion; Cycle 1, Day 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion
PK: Dose-Normalized Cmax of Gemcitabine
Time frame: Run-In Period Day 1 Cohort 1: 0,0.5,1,1.5,3,4,6.67 and 24h Post Start of Infusion; Cycle 1, Day 1: 0, 0.50, 1, 1.5, 3, 4.67, 6.67 and 24 h Post Start of Infusion
PK: Dose-Normalized Cmax of Cisplatin
Time frame: Run-In Period Day 1 Cohort 1: 0, 2, 2.03, 2.25, 3, 3.67 and 5.67 h Post Start of Infusion; Cycle 1, Day 1: 0, 2, 2.03, 2.25, 3, 3.67 and 5.67 h Post Start of Infusion
PK: Area Under Concentration-Time Curve From Zero to Time 168 (AUC[-168]) of Necitumumab
Time frame: Run-In Period Day 3 Cohort 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion; Cycle 1, Day 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion
PK: Dose-Normalized AUC(0-24) of Gemcitabine
Time frame: Run-In Period Day 1 Cohort 1: 0,0.5,1,1.5,3,4,6.67 and 24h Post Start of Infusion; Cycle 1, Day 1: 0, 0.50, 1, 1.5, 3, 4.67, 6.67 and 24 h Post Start of Infusion
PK: Dose-Normalized AUC(0-5) of Cisplatin
Time frame: Run-In Period Day 1 Cohort 1: 0, 2, 2.03, 2.25, 3, 3.67 and 5.67 h Post Start of Infusion; Cycle 1, Day 1: 0, 2, 2.03, 2.25, 3, 3.67 and 5.67 h Post Start of Infusion
PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, (AUC[0-∞]) of Necitumumab
Time frame: Run-In Period Day 3 Cohort 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion; Cycle 1 Day 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion
PK: Dose Normalized AUC(0-∞) of Gemcitabine
Time frame: Run-In Period Day 1 Cohort 1: 0,0.5,1,1.5,3,4,6.67 and 24h Post Start of Infusion; Cycle 1, Day 1: 0, 0.50, 1, 1.5, 3, 4.67, 6.67 and 24 h Post Start of Infusion
Number of Participants With Anti-Necitumumab Antibodies
A participant was considered to have an anti-necitumumab antibody response if anti-drug antibodies (ADA) were confirmed positive. Treatment emergent antibodies were defined as any anti-necitumumab antibody titer equal to or greater than 4-fold the participant's baseline titer.
Time frame: Baseline through, 30-Day Follow-Up
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (Antitumor Activity of Necitumumab in Combination With Gemcitabine-cisplatin Chemotherapy)
ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.1, CR was defined as the disappearance of all target and non-target lesions; PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) \* 100.
Time frame: Baseline to Measured Progressive Disease (Up to 14 Months)
PK: Cmax of Necitumumab After Administration of Process C and Process D Drug Product
Time frame: Run-In Period Day 3 Cohort 1 and Cohort 2: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion
PK: AUC(0-∞) of Necitumumab After Administration of Process C and Process D Drug Product
Time frame: Run-In Period Day 3 Cohort 1 and Cohort 2: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion
| Milestone | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| Started | 18 | 17 |
| Received at least 1 dose of study drug | 18 | 17 |
| Completed | 15 | 17 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| microgram/milliliter (ug/mL) | Necitumumab Cohort 1 Day 3 Run-in | Necitumumab Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab | 277 ± 22 | 315 ± 23 |
| nanogram(ng)/mL/mg | Gemcitabine Cohort 1 Day 1 PK Run-In | Gemcitabine Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Dose-Normalized Cmax of Gemcitabine | 4.83 ± 66 | 7.87 ± 43 |
| nanogram (ng)/mL/mg | Cisplatin Cohort 1 Day 1 Run-in | Cisplatin Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Dose-Normalized Cmax of Cisplatin | 19.2 ± 21 | 22.1 ± 30 |
| ug*hour(h)/mL | Necitumumab Cohort 1 Day 3 Run-In | Necitumumab Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Area Under Concentration-Time Curve From Zero to Time 168 (AUC[-168]) of Necitumumab | 21900 ± 24 | 22900 ± 34 |
A participant was considered to have an anti-necitumumab antibody response if anti-drug antibodies (ADA) were confirmed positive. Treatment emergent antibodies were defined as any anti-necitumumab antibody titer equal to or greater than 4-fold the participant's baseline titer.
| participants with immunogenicity samples | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| ADA Positive | 3 | 0 |
| TE Antibodies | 1 | 0 |
| Neutralizing Antibodies | 0 | 0 |
ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.1, CR was defined as the disappearance of all target and non-target lesions; PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) \* 100.
| percentage of participants | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (Antitumor Activity of Necitumumab in Combination With Gemcitabine-cisplatin Chemotherapy) | 16.7 (3.6 to 41.4) | 5.9 (0.1 to 28.7) |
| ug/mL | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| PK: Cmax of Necitumumab After Administration of Process C and Process D Drug Product | 277 ± 22 | 300 ± 36 |
| ng*h/mL/mg | Gemcitabine Cohort 1 Day 1 PK Run-in | Gemcitabine Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Dose-Normalized AUC(0-24) of Gemcitabine | 2.71 ± 45 | 3.31 ± 33 |
| ug*h/mL | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| PK: AUC(0-∞) of Necitumumab After Administration of Process C and Process D Drug Product | 33800 ± 33 | 35500 ± 35 |
| ng*h/mL/mg | Cisplatin Cohort 1 Day 1 Run-in | Cisplatin Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Dose-Normalized AUC(0-5) of Cisplatin | 61.5 ± 20 | 67.3 ± 24 |
| ug*h/mL | Necitumumab Cohort 1 Day 3 PK Run-In | Necitumumab Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, (AUC[0-∞]) of Necitumumab | 33800 ± 33 | 26400 ± 30 |
| ng*h/mL/mg | Gemcitabine Cohort 1 Day 1 PK Run-in | Gemcitabine Cohort 1 Day 1, Cycle 1, Combination |
|---|---|---|
| PK: Dose Normalized AUC(0-∞) of Gemcitabine | 2.72 ± 45 | 3.32 ± 33 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Necitumumab Cohort 1 | — | 5/18 (27.8%) | 18/18 (100%) |
| Necitumumab Cohort 2 | — | 8/17 (47.1%) | 17/17 (100%) |
| Event | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/18 | 2/17 |
| PancytopeniaBlood and lymphatic system disorders | 0/18 | 1/17 |
| NauseaGastrointestinal disorders | 0/18 | 1/17 |
| Small intestinal obstructionGastrointestinal disorders | 0/18 | 1/17 |
| AstheniaGeneral disorders | 0/18 | 1/17 |
| Urinary tract infection bacterialInfections and infestations | 0/18 | 1/17 |
| FallInjury, poisoning and procedural complications | 0/18 | 1/17 |
| Decreased appetiteMetabolism and nutrition disorders | 0/18 | 1/17 |
| HypokalaemiaMetabolism and nutrition disorders | 0/18 | 1/17 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/18 | 1/17 |
| Event | Necitumumab Cohort 1 | Necitumumab Cohort 2 |
|---|---|---|
| FatigueGeneral disorders | 14/18 | 13/17 |
| AnaemiaBlood and lymphatic system disorders | 10/18 | 13/17 |
| HypomagnesaemiaMetabolism and nutrition disorders | 10/18 | 12/17 |
| NauseaGastrointestinal disorders | 12/18 | 10/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/18 | 6/17 |
| Aspartate aminotransferase increasedInvestigations | 11/18 | 8/17 |
| VomitingGastrointestinal disorders | 10/18 | 6/17 |
| White blood cell count decreasedInvestigations | 10/18 | 7/17 |
| NeutropeniaBlood and lymphatic system disorders | 8/18 | 9/17 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 4/18 | 9/17 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| Mean | 55.3 ± 15.54 | 58.2 ± 13.84 | 56.7 ± 14.59 |
| Sex: Female, Male(Participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 7 | 7 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 17 | 16 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 3 |
| White | 17 | 14 | 31 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| United States | 18 | 17 | 35 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline(participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| 0 | 9 | 7 | 16 |
| 1 | 9 | 10 | 19 |
| >=2 | 0 | 0 | 0 |
| Disease Characteristics - Tumor Type(participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| Breast Carcinoma | 3 | 4 | 7 |
| Ovarian Carcinoma | 2 | 1 | 3 |
| Small Cell Lung Carcinoma | 2 | 1 | 3 |
| Thymic Tumor | 2 | 0 | 2 |
| Nonsmall Cell Lung Carcinoma | 2 | 0 | 2 |
| Melanoma | 1 | 1 | 2 |
| Head and Neck Carcinoma | 1 | 1 | 2 |
| Endometrial Carcinoma | 1 | 1 | 2 |
| Hepatobilliary Carcinoma | 1 | 0 | 1 |
| Left Parotid | 1 | 0 | 1 |
| Liver | 1 | 0 | 1 |
| Granulosa Cell Tumor of the Ovary | 1 | 0 | 1 |
| Mesothelioma | 0 | 1 | 1 |
| Neuroendocrine Tumor | 0 | 1 | 1 |
| Hepatocellular Carcinoma | 0 | 1 | 1 |
| Esophageal Carcinoma | 0 | 1 | 1 |
| Colorectal Carcinoma | 0 | 1 | 1 |
| Sarcoma, soft tissue | 0 | 1 | 1 |
| Adenocarcinoma of the Ampula of Vater | 0 | 1 | 1 |
| Pancreatic Carcinoma | 0 | 1 | 1 |
| Prior Anti-Cancer Therapy(participants) | Necitumumab Cohort 1 | Necitumumab Cohort 2 | Total |
|---|---|---|---|
| Any Prior Radiotherapy | 13 | 10 | 23 |
| Any Prior (Adjuvant/Neoadjuvant) Systemic Therapy | 17 | 16 | 33 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Aug 2012, a primary completion of Jun 2013 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 3 years 2 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Necitumumab · Gemcitabine · Cisplatin
Carcinoma, Non-Small-Cell Lung →